Abdelaal Amina, El-Ghaffar Hassan Abd, Zaghloul Mohammad Hosam Eldeen, El Mashad Noha, Badran Ehab, Fathy Amal
Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ann Clin Microbiol Antimicrob. 2009 Jan 30;8:4. doi: 10.1186/1476-0711-8-4.
Tuberculosis is a growing international health concern. It is the biggest killer among the infectious diseases in the world today. Early detection of drug resistance allows starting of an appropriate treatment. Resistance to drugs is due to particular genomic mutations in specific genes of Mycobacterium tuberculosis(MTB). The aim of this study was to identify the presence of Isoniazid (INH) and Rifampicin(RIF) drug resistance in new and previously treated tuberculosis (TB) cases using DNA sequencing.
This study was carried out on 153 tuberculous patients with positive Bactec 460 culture for acid fast bacilli.
Of the 153 patients, 105 (68.6%) were new cases and 48 (31.4%) were previously treated cases. Drug susceptibility testing on Bactec revealed 50 resistant cases for one or more of the first line antituberculous. Genotypic analysis was done only for rifampicin resistant specimens (23 cases) and INH resistant specimens (26 cases) to detect mutations responsible for drug resistance by PCR amplification of rpoB gene for rifampicin resistant cases and KatG gene for isoniazid resistant cases. Finally, DNA sequencing was done for detection of mutation within rpoB and KatG genes. Genotypic analysis of RIF resistant cases revealed that 20/23 cases (86.9%) of RIF resistance were having rpoB gene mutation versus 3 cases (13.1%) having no mutation with a high statistical significant difference between them (P < 0.001). Direct sequencing of Kat G gene revealed point mutation in 24/26 (92.3%) and the remaining 2/26 (7.7%) had wild type KatG i.e. no evidence of mutation with a high statistical significant difference between them (P < 0.001).
We can conclude that rifampicin resistance could be used as a useful surrogate marker for estimation of multidrug resistance. In addition, Genotypic method was superior to that of the traditional phenotypic method which is time-consuming taking several weeks or longer.
结核病是一个日益引起国际关注的健康问题。它是当今世界传染病中最大的杀手。早期检测耐药性有助于开始适当的治疗。耐药性是由于结核分枝杆菌(MTB)特定基因中的特定基因组突变所致。本研究的目的是使用DNA测序来确定新诊断和既往治疗过的结核病(TB)病例中异烟肼(INH)和利福平(RIF)耐药性的存在情况。
本研究对153例抗酸杆菌Bactec 460培养阳性的结核患者进行。
153例患者中,105例(68.6%)为新发病例,48例(31.4%)为既往治疗过的病例。Bactec药敏试验显示50例对一种或多种一线抗结核药物耐药。仅对利福平耐药标本(23例)和异烟肼耐药标本(26例)进行基因分型分析,通过对利福平耐药病例的rpoB基因和异烟肼耐药病例的KatG基因进行PCR扩增来检测导致耐药的突变。最后,进行DNA测序以检测rpoB和KatG基因内的突变。利福平耐药病例的基因分型分析显示,20/23例(86.9%)利福平耐药病例存在rpoB基因突变,3例(13.1%)无突变,两者之间存在高度统计学显著差异(P < 0.001)。KatG基因直接测序显示24/26例(92.3%)存在点突变,其余2/26例(7.7%)为野生型KatG,即无突变证据,两者之间存在高度统计学显著差异(P < 0.001)。
我们可以得出结论,利福平耐药性可作为评估多药耐药性的有用替代标志物。此外,基因分型方法优于传统的表型方法,传统表型方法耗时数周或更长时间。